Organigram Global Secures C$65.2M Investment from British American Tobacco Subsidiary
British American Tobacco’s subsidiary subscribed for 14,027,074 Organigram Global shares at C$3.00 and obtained top-up rights for 9,897,356 shares at C$2.335854, totaling C$65.2 million in gross proceeds. The funding secures cash for the €113.4 million Sanity Group acquisition upfront payment, covers transaction expenses and boosts Organigram’s working capital.
1. Investment Terms
British American Tobacco’s subsidiary will subscribe for 14,027,074 Organigram Global shares at C$3.00 each and holds top-up rights for 9,897,356 shares at C$2.335854, delivering C$65.2 million in gross proceeds.
2. Purpose of Funding
Proceeds will fund the €113.4 million upfront payment for the Sanity Group acquisition, related transaction expenses and general working capital needs, reducing funding uncertainty for the deal.
3. Strategic Significance
The confirmed backing underscores BTI’s commitment to building a global cannabis platform by supporting Organigram’s European expansion and reinforces confidence in the combined company’s growth prospects.
4. Market and Technical Reaction
Following the announcement, Organigram Global shares jumped 8.7% premarket, trading above their 20-day simple moving average but below the 100-day average; RSI stands at 41.3 and MACD indicates mild bearish pressure, suggesting mixed momentum.